SCHEMBL9907394

SCHEMBL9907394

Cc1cccc(-c2ccnc3ccc(C(=O)O)cc23)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.43
CSNK2B P67870 2/20 0.43
KDM4C Q9H3R0 2/20 0.43
KDM5A P29375 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
TDP1 Q9NUW8 2/20 0.41
TGFBR1 P36897 2/20 0.40
GAK O14976 1/20 0.40
RIPK2 O43353 1/20 0.40
MAP4K4 O95819 1/20 0.40
KDR P35968 1/20 0.40
ACVR1B P36896 1/20 0.40
TGFBR2 P37173 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
TGFB2 P61812 1/20 0.40
MAPK14 Q16539 1/20 0.40
MINK1 Q8N4C8 1/20 0.40
COQ8A Q8NI60 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907406 0.87 KDM4C (0.52) CSNK2A2CSNK2BKDM4CKDM5AKDM5B
SCHEMBL9907393 0.87 HTT (0.51) TGFBR1NUDT1MEN1KMT2APOLB
SCHEMBL9907371 0.85 KMO (0.53) CSNK2A2CSNK2BKDM4CKDM5AKDM5B
SCHEMBL9907810 0.84 HTR5A (0.53)
SCHEMBL9909198 0.83 KMO (0.43) IP6K1IP6K3IP6K2MRGPRX4
SCHEMBL9907470 0.80 CSNK2A2 (0.41) CSNK2A2CSNK2BKDM4CKDM5AKDM5B
SCHEMBL9925388 0.80 CSNK2A2 (0.41) CSNK2A2CSNK2BKDM4CKDM5AKDM5B
SCHEMBL21083359 0.80 TGFBR1 (0.51) KDM4CTGFBR1GAKRIPK2MAP4K4
SCHEMBL9907403 0.79 JAK2 (0.45) KDM4CKDM5AKDM5BTDP1IP6K1
SCHEMBL9907412 0.78 KMO (0.50) KDM5AKDM5BTDP1IP6K1IP6K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E CSNK2A2 4132/4885CSNK2B 4303/4885KDM4C 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.